

Research & Development – end of year report. April 2018



Agenda Item No: 9.3

Trust Board Report

Meeting Date:	30 th April 2018
Title:	Research & Development – end of year report.
Executive Summary:	<p>This report reflects R&D performance from April 2017 up to end March 2018.</p> <p><u>Key achievements:</u></p> <ul style="list-style-type: none"> • A total of 2383 participants have been recruited into research studies across the Trust during 17/18. • 2298 participants were recruited into Portfolio studies*. This is 115% against the annual target set by the Trust (2000) and 75% against CRNWM set target (3045). • The R&D Directorate continues to provide alternatives to existing patient care, treatment and choice. • Research activity across a broad range of clinical specialties – not reliant on one study for recruitment. • Feedback from research participants confirms that they value the opportunity to take part in research and that they feel supported and cared for when doing so. • CRN: West Midlands core funding of £1,088,495 allocated – no underspend reported. • This sum represents a large reduction in core funding and will necessitate a restructuring of the department with a threat to research capability in the future <p>*Based on data uploaded to EDGE CPMS as at 16/04/18</p> <p>This report was submitted to the TMC meeting on 27th April 2018.</p>
Action Requested:	Receive and note performance report.
For the attention of the Board	
Assure	<ul style="list-style-type: none"> • This report summarises the performance of the Trust against the NIHR High Level Indicators for research delivery for 2017/18. • The report also includes updates with regards to Finance, Governance and Patient and Public Involvement activity within R&D.
Author + Contact Details:	Tel 01902 307999 extn.4218 Email jamescotton@nhs.net Prof. James Cotton, R&D Director.
Links to Trust Strategic Objectives	<ol style="list-style-type: none"> 1. Create a culture of compassion, safety and quality 2. Proactively seek opportunities to develop our services 3. To have an effective and well integrated local health and care system that operates efficiently 4. Attract, retain and develop our staff, and improve employee engagement 5. Maintain financial health – Appropriate investment to patient services 6. Be in the top 25% of all key performance indicators

Resource Implications:	None
CQC Domains	<p>Safe: patients, staff and the public are protected from abuse and avoidable harm.</p> <p>Effective: care, treatment and support achieves good outcomes, helping people maintain quality of life and is based on the best available evidence.</p> <p>Caring: staff involve and treat everyone with compassion, kindness, dignity and respect.</p> <p>Responsive: services are organised so that they meet people's needs.</p> <p>Well-led: the leadership, management and governance of the organisation make sure it's providing high-quality care that's based around individual needs, that it encourages learning and innovation, and that it promotes an open and fair culture.</p>
Equality and Diversity Impact	None
Risks: BAF/ TRR	n/a
Public or Private:	Public
Other formal bodies involved:	Trust Management Committee
NHS Constitution:	<p>In determining this matter, the Board should have regard to the Core principles contained in the Constitution of:</p> <ul style="list-style-type: none"> • Equality of treatment and access to services • High standards of excellence and professionalism • Service user preferences • Cross community working • Best Value • Accountability through local influence and scrutiny



Report Details							
1	<p>NIHR CRN WM Performance Targets (RWT)</p> <p>1.1 <u>NIHR High Level Objective (HLO) 1 – Increase the number of participants recruited into NIHR CRN Portfolio studies.</u></p> <p>Table (a) provides study recruitment for the Trust into NIHR Portfolio studies during 17/18.</p> <p style="text-align: center;"><i>Table (a) – Portfolio Study Recruitment</i></p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th style="background-color: #D9E1F2;">No. of participants recruited 2017-18</th> <th style="background-color: #D9E1F2;">% Recruitment against Trust target (2000)</th> <th style="background-color: #D9E1F2;">% Recruitment against CRN WM target (3045)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2298</td> <td style="text-align: center;">115%</td> <td style="text-align: center;">75%</td> </tr> </tbody> </table> <p>1.2 <u>NIHR HLO 2 – Increase the proportion of studies recruiting to time and target.</u></p> <p>Of the 48 studies that closed during 2017/18:</p> <p>(a) 76% of commercial studies and</p> <p>(b) 37% of non-commercial studies recruited to time and target.</p>	No. of participants recruited 2017-18	% Recruitment against Trust target (2000)	% Recruitment against CRN WM target (3045)	2298	115%	75%
No. of participants recruited 2017-18	% Recruitment against Trust target (2000)	% Recruitment against CRN WM target (3045)					
2298	115%	75%					

The target for this indicator is 80%.
Overall performance across the CRN WM for this indicator is 64% and 76% respectively.

1.3 NIHR HLO 3 – Increase the number of commercial contract studies

19 commercial portfolio studies were opened at RWT during 2017/18.

1.4 NIHR HLO 4 – Proportion of studies achieving set up at site within 40 calendar days

At RWT, 65% of studies were set-up within 40 days during 2017/18.

The target for this indicator is 80%.
Overall performance across the CRN WM for this indicator is 60%.

1.5 NIHR HLO 5 – Proportion of studies achieving first participant recruited within 30 days of date site confirmed

Of the 28 studies opened and recruited to during 2017/18,
(a) 23% of commercial studies and
(b) 53% of non-commercial studies recruited first participant within 30 days.

The target for this indicator is 80%.
Overall performance across the CRN WM for this indicator is 26% and 56% respectively.

2 Overall Research Performance

2.1 Overall research recruitment and activity across the Trust for 2017/18 is given in table (b) below and further detailed in Appendix 1.

Table (b) – All Study Recruitment

Study Category	Recruitment 17/18
Portfolio - non-commercial	1974
Portfolio - commercial	324
Non-commercial (other)	85
Commercial (direct)	0
Total	2383

3 Finance

3.1 2017/18 Research Funding

The R&D Directorate has received the following funding to support Trust research activity during 17/18:

- *CRN: West Midlands Allocation*
 - Core Funding £1,088,495
 - Additional in-year funding to support delivery £44,832

This allocation represents a £157,230 decrease in funding from 16/17 and £396,122 from 15/16. All funding has been allocated, with a breakeven position reported at year end.

	<ul style="list-style-type: none"> • <i>Commercial Research Income</i> <ul style="list-style-type: none"> - Invoices based on contracted research activity £1,005,937 <p>This amount is slightly lower (£23k) than that received in 2016/17.</p>
4	<p>Patient & Public Involvement</p> <p>4.1 <u>Publicity and Communication</u></p> <ul style="list-style-type: none"> • A dedicated twitter account, managed by the Trust communications team, for research at RWT went live in early 2018: @RWTResearch • A growing number of individuals, research organisations and sponsors are following this account to hear about innovative research taking place at RWT. <p>4.2 <u>Research Participant Questionnaire</u></p> <p>The R&D Directorate continue to proactively seek the views of research participants via a questionnaire distributed to participants recruited into studies during the preceeding 6-12 months.</p> <p>In October 2017, 554 research participants received questionnaires enquiring about their experiences of taking part in research. 195 were returned (35% response rate). Overall results show</p> <ul style="list-style-type: none"> • 86% of respondents felt the care provided to them by the research team was of the highest standard. • 87% said that they felt supported throughout their study. • 96% felt their privacy and dignity was maintained throughout the study. • 80% would take part in further research • 78% would recommend it to a friend or family member. <p>The full results of this survey are available from the R&D Department. Specialty results will also be provided to enable research teams and Directorates to receive feedback regarding their studies.</p>
5	<p>Governance</p> <p>As part of our on-going commitment to quality and performance, the R&D Directorate continues to review and support quality assurance in line with European and UK regulator standards.</p> <p>5.1 <u>External Inspections.</u></p> <ul style="list-style-type: none"> • For the period of 1st April to 31st March 2018, 254 monitoring site visits have been conducted by study sponsors. • No external inspections for regulatory purposes relating to research activities were undertaken during 2017/18. <p>5.2 <u>Annual Audit Programme</u></p> <p>18 audits were completed during the year, as per audit plan.</p>

	Total
Delegation Log Audit	1
Consent Audit	1
External Access to Clinical Portal	12
Study Site File Audits	1
Out of Hours Process	2
Monitor Reports Audit	1
	18

Audit results are reported to the R&D Directorate Governance meeting and action plans agreed as necessary.

6 Wolverhampton University/RWT Update

During 2017/18, Professor for Clinical Practice and Innovation, Magi Sque, working in partnership with The Royal Wolverhampton NHS Trust and University of Wolverhampton researchers has been involved in the following:

- Led the development, launch and roll-out of the new Trust Research Strategy for caring science professionals, *Stepping up for Research, 2017-2021*.
- Contributed to the work of the Bereavement Steering Group by supporting End of Life (Swan) study days and the development of a new Bereavement Care Questionnaire to evaluate the experiences of bereaved families whose relative/friend died while in the care of Royal Wolverhampton NHS Trust.
- Gave four oral presentations at two European conferences i.e. *Donation after circulatory death: A case study*, and *Recognising the gift of organ and tissue donation: an evidence-based approach* at The International Society for Organ Donation and Procurement Biennial Congress, Geneva, Switzerland, 07 September 2017; and *An ethical framework for researching the bereaved* and *Ethical issues in bereavement research: Practical use of a decision-making framework* at The Present and Future Challenges and Opportunities for Ethics in Nursing and Care, 18th Nursing Ethics Conference, 3rd International Ethics in Care Conference, Leuven, Belgium, 15 September 2017.
- Member of the Organising Committee and speaker at Interfaith Wolverhampton Conference on Organ Donation, held at the Gujarati Centre, Wolverhampton, 18 November 2017
- External Partner and Supporter of Clinical Academic Internship Programme for West Midlands. This prestigious programme provides opportunities for caring science professionals to have an introduction and taster of a clinically-based research career. Two Trust staff successfully recruited to the programme 2017-18.

Appendices

1	Trust Research Activity 2017/18
---	---------------------------------

Appendix 1 – Trust Research Activity 2017/18

April 17 – March18	KPI's									
	Research Active	No. of NIHR Portfolio Trials	Accruals (NIHR Portfolio)	No. of open Non-Portfolio trials	Accruals (Non Portfolio)	No. of own account trials	Active PI's	Active CI's in dept	Linked Research Nurses	Linked CTAs/ AHP's
Division1										
Diagnostic Services Group										
Radiology	Y									
Pathology/Clinical Chemistry	Y	1	229*	1	0	2	2	1	0	0
Theatres/ICCU Service Group	Y	1	3	3	0	0	1	0	1	1
Cardiology/Cardiothoracic Service Group	Y	15	349	3	0	6	9	4	5	2
Surgical Services Group										
General Surgery	Y	1	4	1	0	2	2	2	4	0
Orthopaedics	N									
Urology	Y	6	24	0	0	0	1	0	3	1
Obs & Gynae	Y	11	80	3	0	0	3	0	2	1
Ophthalmology/Head and Neck Services Group	Y	7	22	3	0	1	4	1	3	1
Children's Services Group	Y	13	212	5	0	1	8	1	3	1
Total		55	923	19	0	12	30	9	21	7
Division 2										
Adult Community Services	N									
Rehabilitation & Ambulatory Medical Group	Y	11	78	1	0	0	6	0	3	1
Medical Group										
Respiratory	Y	3	23	3	0	1	2	1	2	1
Gastroenterology & Hepatology	Y	14	398	3	0	2	7	2	2	1
Diabetes	Y	4	51	0	0	1	3	1	1	1
Renal	Y	10	106	5	0	1	3	1	2	1
Rheumatology	Y	21	213	1	78	1	6	1	8	2
Dermatology	Y	3	48	1	0	0	2	0	4	2
Infectious Diseases	Y	2	106	0	0	0	1	0	1	1
Nutrition & Dietetics	N									
Emergency Services Group	Y	1	74	0	0	0	1	0	1	1
Therapies & Pharmacies Group	Y	0	0	2	7	0	2	0	0	0
Oncology & Haematology Group	Y	28	168	12	0	1	21	2	12	4
Total		97	1265	28	85	7	54	8	36	15
Corporate / Health Service Delivery	Y	1	85	20	0	1	8	1	0	0
Genetics	Y	1	25	0	0	0	0	0	0	0
Medical Physics	Y									
Infection Control	N									

*Trust sponsored Portfolio study involving Cardiovascular and Clinical Chemistry – Chief Investigator Prof R. Gama